| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_18d92c46f60af8af24e262b67381d7eb |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2440-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-22 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5091
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2016-02-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6718783775ac6b3fb5e39356ce8ff69b |
| publicationDate |
2016-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2016138520-A1 |
| titleOfInvention |
Assay to diagnose and treat disorders of the alternative pathway of complement activation |
| abstract |
The present invention relates generally to the field of disorders of complement activation. More specifically, the present invention provides methods and compositions useful for diagnosing and treating atypical hemolytic uremic syndrome, antiphospholipid antibody syndrome and other disorders of the alternative pathway of complement activation. In one embodiment, a method comprises the steps of (a) incubating or contacting serum obtained from a patient suspected of having atypical hemolytic uremic syndrome (aHUS) with a glycosylphosphatidylinositol-anchored protein (GPI-AP) deficient cell line; and (b) performing a cell viability assay on the cells from step (a). In a specific embodiment, the method further comprises the step of diagnosing the patient as having aHUS based on a statistically significant increased difference of non-viable cells from the patient serum as compared to a control. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020205501-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020219822-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020185541-A2 |
| priorityDate |
2015-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |